Window of Opportunity Study of VS-6063 (Defactinib) in Surgical Resectable Malignant Pleural Mesothelioma Participants
Status:
Terminated
Trial end date:
2019-06-19
Target enrollment:
Participant gender:
Summary
This is an open label neoadjuvant (treatment with VS-6063 prior to mesothelioma surgery)
study in subjects with malignant pleural mesothelioma who are eligible for surgery. Subjects
will receive VS-6063 (defactinib) 400 mg twice daily for 12, 21, or 35 days or 100 mg
formulation twice daily for 21 days. Pre- and post-treatment biopsies and blood samples will
be collected. The purpose of this study is to assess biomarker responses from tumor tissue.
The safety, pharmacokinetics, and tumor response rate to VS-6063 (defactinib) will be also be
assessed.